バイオ医薬品受託製造市場：製品、供給元、サービス、事業規模、治療用途別-2024-2030年世界予測

バイオ医薬品受託製造市場規模は、2023年に182億7,000万米ドルと推定され、2024年には191億6,000万米ドルに達し、CAGR 5.14%で2030年には259億5,000万米ドルに達すると予測されています。

バイオ医薬品の受託製造とは、バイオ医薬品の製造工程を第三者の製造業者に委託することです。これらの専門企業は、ワクチン、モノクローナル抗体、組換えタンパク質、その他の生物由来医薬品を含むバイオ医薬品の製造に必要な専門知識、設備、施設を有しています。この共同アプローチにより、バイオ医薬品企業は外部の能力やリソースを活用し、拡張性を高め、コストを削減し、新治療法の市場投入までの時間を短縮することができます。バイオ医薬品の受託製造市場は、生物学的製剤のパイプラインの増加、バイオシミラーに対する需要の高まり、生物学的製剤の製造工程の複雑化によって牽引されています。専門的な製造能力の必要性、厳格な規制要件、コスト削減と市場投入までの時間短縮の要望が、製薬企業をアウトソーシングへと向かわせる。しかし、バイオ医薬品の製造施設設立には多額の費用がかかるため、市場成長の妨げになる可能性があります。とはいえ、バイオ医薬品の研究開発および製造への投資が増加していることに加え、個別化医療が世界的に重視されるようになっていることから、市場成長の潜在的機会が生まれると予想されます。

サービス規制基準を満たすために不可欠な分析試験とQC試験の利用拡大

分析および品質管理（QC）試験は、バイオ医薬品の安全性、有効性、品質を確保する上で不可欠です。このサービスには、試験法の開発、バリデーション、安定性試験、バッチリリース試験など、さまざまな活動が含まれます。これらの試験は、規制基準を満たし、製造された製品が仕様を満たしていることを保証するために不可欠です。充填および仕上げ作業は、バイオ医薬品の製造工程における重要な段階であり、最終医薬品を容器に無菌充填し、ラベル貼りや包装などの仕上げ作業を行います。この工程では、製品の無菌性と完全性を維持するため、精密さと高水準の清浄度が要求され、バイオ医薬品の受託製造において重要な要素となっています。バイオ医薬品の包装サービスは、単に製品を封入するだけではありません。環境要因から製品を保護し、保管・輸送中の安定性を確保し、規制要件に適合するような包装システムを設計・開発することも含まれます。また、洗練されたパッケージング・ソリューションは、患者の利便性を高め、治療計画の遵守をサポートします。プロセス開発は、バイオ医薬品受託製造における重要なサービスであり、費用対効果、効率性、品質基準の遵守を確実にするための生産プロセスの設計、最適化、スケールアップに焦点を当てています。これには、細胞培養プロセス、精製プロセス、統合プロセス分析の開発が含まれ、商業的製造のためのプロセスの堅牢性と持続可能性を保証します。下流工程では、上流工程で生産された生物学的物質を回収・精製します。この段階は不純物を除去し、製品を濃縮するために重要です。下流工程に関わる技術には、クロマトグラフィー、ろ過、沈殿などがあり、いずれも最終的なバイオ医薬品製品の純度と品質を確保するために不可欠です。上流工程とは、バイオ医薬品製造の初期段階を指し、目的の生物学的物質を生産するために、制御された条件下でバイオリアクター内で細胞を培養することを含みます。このサービスには、細胞株開発、培地調製、バイオリアクター操作の専門知識が必要であり、さらに加工して治療製品として最終化できる生物学的活性物質を生産するための基盤を形成します。

事業規模：バイオ医薬品受託製造：進化する商業的事業規模

バイオ医薬品の受託製造における臨床規模とは、臨床試験を目的としたバイオ医薬品の小～中ロットの製造を指します。この規模では、治験薬の有効性と安全性を保証するために、柔軟性、正確性、規制基準の遵守が優先されます。製造工程は、臨床開発段階における要求事項の変化に対応できるよう設計されており、前臨床試験から第I相、第II相、第III相臨床試験への移行を促進します。この規模では、製品の商業化に近づくにつれて、適応性とプロセスのスケールアップ能力が重視されます。臨床スケールでサービスを提供する製造受託機関（CMO）は、モノクローナル抗体、組換えタンパク質、遺伝子治療を含む複雑な生物製剤を取り扱うための最先端の技術と専門知識を備えており、製品が臨床研究に求められる厳しい品質基準を満たすことを保証しています。バイオ医薬品の受託製造における商業的規模は、規制当局の承認後の大量販売を目的とした大規模生産を伴う。この規模では、効率性、費用対効果、承認されたバイオ医薬品に対する高い需要を満たす能力が重視されます。商業規模の製造には、一貫した製品品質と世界の規制要件への適合を保証するためのインフラ、技術、品質管理システムへの多大な投資が必要となります。商業規模の製造受託企業は、製造プロセスを最適化し、サプライチェーンを効率的に管理し、大量のバイオ医薬品をタイムリーに供給する能力を有しています。この規模の事業では、バイオ医薬品業界の厳しい基準を満たし、世界中の人々の健康ニーズに対応するため、卓越したオペレーション、プロセスの最適化、適正製造基準（GMP）の遵守に継続的に取り組んでいることが特徴です。

地域別インサイト

南北アメリカは、高度な技術インフラ、強固な規制の枠組み、バイオテクノロジー研究への多額の投資により、バイオ医薬品受託製造にとって重要な市場となっています。最近のイニシアチブは精密医療と生物製剤に重点を置いており、バイオプロセスと遺伝子工学技術において多数の特許が申請されています。さらに、モノクローナル抗体やワクチンの研究に重点が置かれていることから、世界の医薬品製造受託機関（CMO）がこの国に投資するようになった。アジア太平洋地域のバイオ医薬品受託製造セクターは、製造能力のアップグレードと生物製剤生産の強化により、活況を呈しており、細胞療法と組み換えタンパク質医薬品に多額の投資が行われています。さらに、バイオリアクター技術や再生医療における重要な特許、国内外市場向けのバイオシミラーやワクチンへの注目が投資や提携を後押しし、CMOに多くの機会を提供しています。欧州連合（EU）は、その先進的なヘルスケア・インフラと強力な規制基準に支えられ、バイオ医薬品受託製造市場の成長を示しています。最近の動向では、生物製剤の生産が急増し、個別化医薬品や細胞治療への関心が高まっています。中東はまだ始まったばかりであるが、バイオ医薬品の受託製造が徐々に進んでおり、医療ニーズの高まりに対応するため、ワクチン製造やバイオシミラーへの投資が中心となっています。アフリカのバイオ医薬品受託製造は、ワクチンや一般的な治療薬に重点を置き、輸入医薬品への依存を減らすために現地製造能力の確立に重点を置いているため、発展しつつあります。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、バイオ医薬品受託製造市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、バイオ医薬品受託製造市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.バイオ医薬品受託製造市場の市場規模および予測は？

2.バイオ医薬品受託製造市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.バイオ医薬品受託製造市場の技術動向と規制枠組みは？

4.バイオ医薬品受託製造市場における主要ベンダーの市場シェアは？

5.バイオ医薬品受託製造市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加
    • CMO数の増加と先進製造技術への投資の増加
    • バイオ医薬品企業によるアウトソーシングの増加
  • 抑制要因
    • バイオ医薬品の生産施設の設置にかかる高額な費用
  • 機会
    • バイオ医薬品の研究開発と製造への投資の増加
    • 世界的に個別化医療の重要性が高まっている
  • 課題
    • CMOに対する厳格な規制要件
• 市場セグメンテーション分析
  • サービス：規制基準を満たすために重要な分析および品質管理研究の利用が急増
  • 事業規模：バイオ医薬品受託製造の事業規模の拡大
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 バイオ医薬品受託製造市場：製品別

• 生物学的製剤
• バイオシミラー

第7章 バイオ医薬品受託製造市場：ソース別

• 哺乳類
• 非哺乳類

第8章 バイオ医薬品受託製造市場：サービス別

• 分析および品質管理研究
• 充填および仕上げ作業
• パッケージ
• プロセス開発

第9章 バイオ医薬品受託製造市場事業規模別

• 臨床
• 商業用

第10章 バイオ医薬品受託製造市場治療アプリケーション

• 心血管疾患
• 感染症
• 神経学
• 腫瘍学
• 眼科
• 呼吸器疾患

第11章 南北アメリカのバイオ医薬品受託製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のバイオ医薬品受託製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのバイオ医薬品受託製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • SwiftPharmaとPlantForm Corporationは、植物由来のバイオシミラーに関する新たな契約製造契約を締結し、大ヒットのがん治療薬の開発を目指しています。
  • サムスンバイオロジクス、ブリストル・マイヤーズスクイブとの戦略的製造契約を拡大
  • ヒクマとSKバイオファーマシューティカルズが戦略的提携を締結
• 戦略分析と提言

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET DYNAMICS
• FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 105. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 106. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 107. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 108. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 109. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 110. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 111. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 112. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 113. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 114. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 115. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 116. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 117. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 118. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 119. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 120. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 129. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 130. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 131. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 132. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 133. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 134. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 143. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 144. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 145. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 146. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 147. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 148. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 149. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 150. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 158. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 160. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 161. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 162. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 163. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 164. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 165. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 166. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 169. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 170. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 171. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 172. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 173. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 174. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 175. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 176. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 177. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 178. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 179. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 180. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 181. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 182. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 183. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 184. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 185. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 186. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 187. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 188. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 189. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 190. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 191. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 192. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 193. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 194. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 195. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 196. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 197. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 198. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 199. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 200. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 201. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 202. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 203. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 204. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 205. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 206. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 207. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 208. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 209. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 210. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 211. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 212. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 213. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 214. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 215. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 216. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 217. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 218. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 219. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 220. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 221. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 222. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 223. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 224. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 225. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 226. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 227. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 228. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 229. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 230. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 231. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 232. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 233. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 234. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 235. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 236. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 237. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 238. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 239. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 240. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 241. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 242. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 243. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 244. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 245. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 246. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 247. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 248. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 249. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 250. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 251. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 252. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 253. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 254. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 255. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 256. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 257. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 258. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 259. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 260. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 261. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 262. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 263. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 264. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 265. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 266. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 267. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2023 (USD MILLION)
• TABLE 268. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2024-2030 (USD MILLION)
• TABLE 269. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 270. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 271. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 272. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 273. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 274. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 275. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 276. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 277. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 278. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 279. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)

TABL

[186 Pages Report] The Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 18.27 billion in 2023 and expected to reach USD 19.16 billion in 2024, at a CAGR 5.14% to reach USD 25.95 billion by 2030.

Biopharmaceutical contract manufacturing is the outsourcing of biopharmaceutical production processes to third-party manufacturers. These specialized entities possess the expertise, equipment, and facilities required to manufacture biopharmaceutical products, which include vaccines, monoclonal antibodies, recombinant proteins, and other biologically derived pharmaceuticals. This collaborative approach enables biopharmaceutical companies to leverage external capabilities and resources to enhance scalability, reduce costs, and accelerate the time to market for new therapies. The biopharmaceutical contract manufacturing market is driven by an increasing pipeline of biologic drugs, rising demand for biosimilars, and the complexity of biologic drug production processes. The need for specialized manufacturing capabilities, stringent regulatory requirements, and the desire to reduce costs and time-to-market push pharmaceutical companies toward outsourcing. However, the high price of setting up a production facility for biopharmaceuticals may hinder market growth. Nevertheless, rising investments in biopharmaceutical R&D and manufacturing, coupled with a growing emphasis on personalized medicine globally, are expected to create potential opportunities for market growth.

Services: Proliferating utilization of analytical and QC studies critical for meeting regulatory standards

Analytical and quality control (QC) studies are vital in ensuring the safety, efficacy, and quality of biopharmaceutical products. This service encompasses a range of activities, including method development, validation, stability testing, and batch release testing. These studies are critical for meeting regulatory standards and ensuring manufactured products meet specifications. Fill and finish operations are a crucial stage in the manufacturing process of biopharmaceuticals, involving the aseptic filling of the final drug into its container, followed by finishing tasks such as labeling and packaging. This process requires precision and high standards of cleanliness to maintain the sterility and integrity of the product, making it a critical component in the contract manufacturing of biopharmaceuticals. Packaging services for biopharmaceuticals go beyond simply enclosing the product. They involve designing and developing packaging systems that protect the product from environmental factors, ensure its stability during storage and transport, and comply with regulatory requirements. Sophisticated packaging solutions also provide patient convenience and support compliance with treatment regimens. Process development is a critical service in biopharmaceuticals contract manufacturing, focusing on designing, optimizing, and scaling up production processes to ensure cost-effectiveness, efficiency, and compliance with quality standards. This includes the development of cell culture processes, purification processes, and integration process analytics to ensure the process is robust and sustainable for commercial manufacturing. Downstream processing involves recovering and purifying biological substances produced during upstream processing. This phase is critical for removing impurities and concentrating the product. Techniques involved in downstream processes include chromatography, filtration, and precipitation, all of which are essential for ensuring the purity and quality of the final biopharmaceutical product. Upstream Processing refers to the initial phase of biopharmaceutical manufacturing, which involves cultivating cells in bioreactors under controlled conditions to produce the desired biological substance. This service requires expertise in cell line development, media preparation, and bioreactor operation, forming the foundation for producing biologically active substances that can be further processed and finalized as therapeutic products.

Scale of Operation: Evolving commercial scale of operation for biopharmaceuticals contract manufacturing

The clinical scale of operation in biopharmaceutical contract manufacturing refers to producing small to medium batches of biopharmaceutical products intended for clinical trials. This scale prioritizes flexibility, precision, and compliance with regulatory standards to assure the efficacy and safety of products under investigation. The production processes are designed to accommodate the evolving requirements of clinical development stages, facilitating the transition from preclinical studies to Phase I, II, and III clinical trials. At this scale, the focus is on adaptability and the ability to scale up processes as the product moves closer to commercialization. Contract manufacturing organizations (CMOs) offering services at the clinical scale are equipped with cutting-edge technology and expertise to handle complex biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, ensuring that products meet the stringent quality standards required for clinical research. The commercial scale of operation in biopharmaceutical contract manufacturing involves large-scale production intended for the mass market following regulatory approval. This scale focuses on efficiency, cost-effectiveness, and the ability to meet the high demand for approved biopharmaceutical products. Commercial-scale manufacturing requires a significant investment in infrastructure, technology, and quality control systems to assure consistent product quality and compliance with global regulatory requirements. Contract manufacturing organizations serving at the commercial scale have the capabilities to optimize production processes, manage supply chains effectively, and ensure the timely delivery of large quantities of biopharmaceuticals. This scale of operation is characterized by a continuous commitment to operational excellence, process optimization, and adherence to Good Manufacturing Practices (GMP) to meet the stringent standards of the biopharmaceutical industry and address the health needs of populations globally.

Regional Insights

The Americas represent a significant market for biopharmaceuticals contract manufacturing, attributed to its advanced technological infrastructure, robust regulatory framework, and significant investments in biotech research. Recent initiatives focus on precision medicine and biologics, with numerous patents filed in bioprocessing and genetic engineering technologies. In addition, the emphasis on research in monoclonal antibodies and vaccines has attracted global contract manufacturing organizations (CMOs) to invest in the country. The biopharmaceutical contract manufacturing sector in Asia Pacific is booming, owing to the upgrading of manufacturing capabilities and enhancement of biologics production, with considerable investments in cell therapy and recombinant protein drugs. Furthermore, significant patents in bioreactor technologies and regenerative medicine and the focus on biosimilars and vaccines for domestic and international markets propel investments and collaborations, offering numerous opportunities for CMOs. The European Union exhibits growth in the biopharmaceuticals contract manufacturing market, supported by its advanced healthcare infrastructure and strong regulatory standards. Recent trends indicate a surge in biologics production and a growing interest in personalized medicines and cell therapies. Despite being nascent, the Middle East is gradually advancing in biopharmaceutical contract manufacturing, with investments focusing on vaccine production and biosimilars to address the rising healthcare needs. Africa's biopharmaceutical contract manufacturing is developing due to the region's focus on establishing local manufacturing capabilities to reduce dependency on imported drugs, emphasizing vaccines and common therapeutics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biopharmaceuticals Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biopharmaceuticals Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include 3P Biopharmaceuticals, AbbVie, Inc., Aenova Group GmbH, AGC Biologics, Ajinomoto Co., Inc., Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Celonic AG, FUJIFILM Diosynth Biotechnologies, INCOG BioPharma Services, Inc., JRS PHARMA GmbH + Co. KG, KBI Biopharma Inc, Lonza AG, Merck KGaA, Pressure BioSciences, Inc. by Emergent Health Corp., ProBioGen AG, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc., Toyobo Co., Ltd., and WuXi Biologics, Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Biologics
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Vaccines

• Biosimilar

• Source
  • Mammalian
  • Non-Mammalian

• Services
  • Analytical & QC studies
  • Fill & Finish Operations
  • Packaging
  • Process Development
    • Downstream
    • Upstream
• Scale of Operation
  • Clinical
  • Commercial

• Therapeutic Applications
  • Cardiovascular Diseases
  • Infectious Disease
  • Neurology
  • Oncology
  • Ophthalmology
  • Respiratory Disorder

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biopharmaceuticals Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biopharmaceuticals Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Biopharmaceuticals Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Biopharmaceuticals Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Biopharmaceuticals Contract Manufacturing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of chronic diseases
    • 5.1.1.2. Increasing number of CMOs and rising investments in advanced manufacturing technologies
    • 5.1.1.3. Rising outsourcing by biopharmaceutical companies
  • 5.1.2. Restraints
    • 5.1.2.1. High price of setting up a production facility for biopharmaceuticals
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investments in biopharmaceutical R&D and manufacturing
    • 5.1.3.2. Growing emphasis on personalized medicine globally
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements for CMOs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Services: Proliferating utilization of analytical and QC studies critical for meeting regulatory standards
  • 5.2.2. Scale of Operation: Evolving commercial scale of operation for biopharmaceuticals contract manufacturing
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Biopharmaceuticals Contract Manufacturing Market, by Product

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Biosimilar

7. Biopharmaceuticals Contract Manufacturing Market, by Source

• 7.1. Introduction
• 7.2. Mammalian
• 7.3. Non-Mammalian

8. Biopharmaceuticals Contract Manufacturing Market, by Services

• 8.1. Introduction
• 8.2. Analytical & QC studies
• 8.3. Fill & Finish Operations
• 8.4. Packaging
• 8.5. Process Development

9. Biopharmaceuticals Contract Manufacturing Market, by Scale of Operation

• 9.1. Introduction
• 9.2. Clinical
• 9.3. Commercial

10. Biopharmaceuticals Contract Manufacturing Market, by Therapeutic Applications

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
• 10.3. Infectious Disease
• 10.4. Neurology
• 10.5. Oncology
• 10.6. Ophthalmology
• 10.7. Respiratory Disorder

11. Americas Biopharmaceuticals Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. SwiftPharma and PlantForm Corporation target blockbuster cancer drug with new contract manufacturing agreement for plant-made biosimilars
  • 14.3.2. Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb
  • 14.3.3. Hikma and SK Biopharmaceuticals enter a strategic partnership
• 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio